Literature DB >> 16365016

Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry.

Matilde E Lleonart1, Gregory D Kirk, Stephanie Villar, Olufunmilayo A Lesi, Abhijit Dasgupta, James J Goedert, Maimuna Mendy, Monica C Hollstein, Ruggero Montesano, John D Groopman, Pierre Hainaut, Marlin D Friesen.   

Abstract

A mutation in codon 249 of the TP53 gene (249(Ser)), related to aflatoxin B(1) exposure, has previously been associated with hepatocellular carcinoma risk. Using a novel internal standard plasmid, plasma concentrations of 249(Ser)-mutated DNA were quantified by electrospray ionization mass spectrometry in 89 hepatocellular carcinoma cases, 42 cirrhotic patients, and 131 nonliver diseased control subjects, all from highly aflatoxin-exposed regions of The Gambia. The hepatocellular carcinoma cases had higher median plasma concentrations of 249(Ser) (2,800 copies/mL; interquartile range: 500-11,000) compared with either cirrhotic (500 copies/mL; interquartile range: 500-2,600) or control subjects (500 copies/mL; interquartile range: 500-2,000; P < 0.05). About half (52%) of the hepatocellular carcinoma cases had >2,500 copies of 249(Ser)/mL plasma, corresponding to the prevalence of this mutation in liver tumors in The Gambia. In comparison, only 15% of control group and 26% of cirrhotic participants exceeded this level (P < 0.05). Further subset analysis revealed a statistically significant, quantitative relation between diagnosis of hepatocellular carcinoma and levels of 249(Ser) detected at 2,501 to 10,000 copies/mL plasma (odds ratio, 3.8; 95% confidence interval, 1.3-10.9) and at >10,000 copies/mL plasma (odds ratio, 62; 95% confidence interval, 4.7-820) when compared with control subjects and after adjusting for age, gender, recruitment site, hepatitis B and C serologic status, and total DNA concentration. Levels of >10,000 copies of 249(Ser)/mL plasma were also significantly associated with the diagnosis of hepatocellular carcinoma (odds ratio, 15; 95% confidence interval, 1.6-140) when compared with cirrhotic patients. Potential applications for the quantification of 249(Ser) DNA in plasma include estimation of long-term, cumulative aflatoxin exposure and selection of appropriate high-risk individuals for targeted intervention.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365016     DOI: 10.1158/1055-9965.EPI-05-0612

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  14 in total

1.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

2.  Mass spectrometric based analysis, characterization and applications of circulating cell free DNA isolated from human body fluids.

Authors:  Vaneet K Sharma; Paul Vouros; James Glick
Journal:  Int J Mass Spectrom       Date:  2011-07       Impact factor: 1.986

3.  TP53 R249S mutation, genetic variations in HBX and risk of hepatocellular carcinoma in The Gambia.

Authors:  Doriane A Gouas; Stphanie Villar; Sandra Ortiz-Cuaran; Pénélope Legros; Gilles Ferro; Gregory D Kirk; Olufunmilayo A Lesi; Maimuna Mendy; Ebrima Bah; Marlin D Friesen; John Groopman; Isabelle Chemin; Pierre Hainaut
Journal:  Carcinogenesis       Date:  2012-06       Impact factor: 4.944

Review 4.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

Review 5.  Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.

Authors:  Ganepola Ap Ganepola; Joel Nizin; John R Rutledge; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-04-15

6.  Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma.

Authors:  Agnès Marchio; Marie Amougou Atsama; Aubin Béré; Narcisse-Patrice Komas; Dominique Noah Noah; Paul Jean Adrien Atangana; Serge-Magloire Camengo-Police; Richard Njouom; Claudine Bekondi; Pascal Pineau
Journal:  Clin Exp Med       Date:  2018-05-10       Impact factor: 3.984

7.  TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations.

Authors:  Behnoush Abedi-Ardekani; Doriane Gouas; Stephanie Villar; Masoud Sotoudeh; Pierre Hainaut
Journal:  Hepat Res Treat       Date:  2011-08-17

8.  Seasonal variation in TP53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.

Authors:  Stéphanie Villar; Emilie Le Roux-Goglin; Doriane A Gouas; Amelie Plymoth; Gilles Ferro; Mathieu Boniol; Myriam Lereau; Ebrima Bah; Andrew J Hall; Christopher P Wild; Maimuna Mendy; Helene Norder; Marianne van der Sande; Hilton Whittle; Marlin D Friesen; John D Groopman; Pierre Hainaut
Journal:  Environ Health Perspect       Date:  2011-07-18       Impact factor: 9.031

9.  Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis.

Authors:  Stephanie Villar; Sandra Ortiz-Cuaran; Behnoush Abedi-Ardekani; Doriane Gouas; Andre Nogueira da Costa; Amelie Plymoth; Thiravud Khuhaprema; Anant Kalalak; Suleeporn Sangrajrang; Marlin D Friesen; John D Groopman; Pierre Hainaut
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa.

Authors:  Mark H Kuniholm; Olufunmilayo A Lesi; Maimuna Mendy; Aliu O Akano; Omar Sam; Andrew J Hall; Hilton Whittle; Ebrima Bah; James J Goedert; Pierre Hainaut; Gregory D Kirk
Journal:  Environ Health Perspect       Date:  2008-07-10       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.